Novel development of combination gene therapy with targeted drug for malignant brain tumor
| Project/Area Number |
17K10865
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
市川 智継 岡山大学, 医歯薬学総合研究科, 准教授 (10362964)
安原 隆雄 岡山大学, 医歯薬学総合研究科, 講師 (50457214)
藤井 謙太郎 岡山大学, 医歯薬学総合研究科, 助教 (40799318)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 分子標的薬 / 遺伝子治療 / 悪性脳腫瘍 / 腫瘍溶解ウイルス / アデノウイルス |
|---|
| Outline of Final Research Achievements |
Gliomas represent approximately 1/3 of primary brain cancer. In spite of different efforts to develop new therapy for gliomas, therapeutic choices remain limited and the prognosis is still poor. Many investigators continue to pursue new therapeutic approaches for glioma including surgery, chemotherapy, radiotherapy, immunotherapy, and combination therapies.
Now we examined the effect of molecular targeted drugs and oncolytic virus or gene therapy. We finished the set up for these experiments. We are investigating synergetic effect for molecular targeted drug and OV or gene therapy. We are trying to perform microarray and pathway analysis. We will show the data for several meetings or papers.
|
| Academic Significance and Societal Importance of the Research Achievements |
分子標的薬と遺伝子治療のそれぞれの効果については確実な再現性のある結果がえられた。今後、併用によって増強する可能性が示唆される。分子標的薬により遺伝子治療効果を増強するメカニズムについては、抗炎症作用やアポトーシスにより、 OV の効果が増強されたというメカニズムの報告があるが、同様なメカニズムが認められるのか、独自のメカニズムがあるのか今後証明されるであろう。悪性神経膠腫は他臓器の悪性腫瘍とくらべて最も予後の悪い腫瘍であり、分子標的薬と遺伝子治療との併用で抗腫瘍効果が得られ、新たな治療法が確立されれば、世界的にも悪性腫瘍研究における breakthrough となる。
|
Report
(4 results)
Research Products
(161 results)
-
-
-
-
[Journal Article] Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma2020
Author(s)
Matsumoto Y , Ichikawa T , Kurozumi K , Otani Y , Fujimura A , Fujii K , Tomita Y , Hattori Y , Uneda A , Tsuboi N , Kaneda K , Makino K , Date I
-
Journal Title
Acta Neuropathologica Communications
Volume: ー
Issue: 1
Pages: 42-42
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogate glioma invasion via the CCN1 and AKT signaling pathways2019
Author(s)
Tomita Y , Kurozumi K , Yoo JY , Ichikawa T , Matsumoto Y , Uneda A , Hattori Y , Shimizu T , Otani Y , Oka T , Kaur B , Date I
-
Journal Title
Molecular Cancer Therapeutics
Volume: 18
Pages: 1418-1429
Related Report
Peer Reviewed / Int'l Joint Research
-
[Journal Article] δ-catenin promotes bevacizumab-induced glioma invasion2019
Author(s)
Shimizu T, Ishida J, Kurozumi K, Ichikawa T, Otani Y, Oka T, Tomita Y, Hattori Y, Uneda A, Matsumoto Y, Date I
-
Journal Title
Molecular Cancer Therapeutics
Volume: 18
Issue: 8
Pages: 812-822
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
[Journal Article] Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.2018
Author(s)
Otani Y , Ichikawa T , Kurozumi K , Inoue S , Ishida J, Oka T , Shimizu T , Tomita Y , Hattori Y , Uneda A, Matsumoto Y , Michiue H, Date I
-
Journal Title
Oncogene
Volume: 37
Pages: 777-786
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion2018
Author(s)
Otani Y , Ichikawa T , Kurozumi K , Inoue S , Ishida J, Oka T , Shimizu T , Tomita Y , Hattori Y , Uneda A, Matsumoto Y , Michiue H, Date I
-
Journal Title
Oncogene
Volume: 37
Pages: 777-786
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Vasculostatin-armed oncolytic herpes virus decreased bevacizumab-induced glioma invasion by regulating CCN1 and AKT signaling pathway2019
Author(s)
Tomita Y , Kurozumi K , Yoo JY , Fujii K , Ichikawa T , Matsumoto Y , Uneda A , Hattori Y , Otani Y , Kaur B , Date I
Organizer
第25回日本遺伝子細胞治療学会
Related Report
Int'l Joint Research
-
-
-
[Presentation] The current status of Ad-SGE-REIC gene therapy for malignant glioma2019
Author(s)
Kurozumi K , Fujii K , Oka T , Hattori Y , Tomita Y , Uneda A , Matsumoto Y , Tsuboi N , Kaneda K , Makino K , Kumon H , Date I
Organizer
24rd Annual Meeting and Education Day of the Society for Neuro-Oncology
Related Report
Int'l Joint Research
-
[Presentation] A phenotypic transition of glioma cells via the ANXA2-STAT3-OSMR axis2019
Author(s)
Matsumoto Y , Ichikawa T , Kurozumi K , Otani Y , Fujimura A , Fujii K , Shimazu Y , Tomita Y , Hattori Y , Uneda A , Tsuboi N , Kaneda K , Makino K , Date I
Organizer
2019 Congress of Neurological Surgeons Annual Meeting: CNS2019
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Correlation between PIK3R1Met326lle mutation, cysteine-rich protein 61 expression and poor prognosis in glioblastoma2017
Author(s)
Kurozumi K, Otani Y, Ishida J, Shimizu T, Tomita Y, Hattori Y, Uneda A, Matsumoto Y, Ichikawa T, Date I
Organizer
The 14th Meeting of the Asian Society for Neuro-Oncology (ASNO 2017)
Related Report
Int'l Joint Research
-
-
-
-
-
-
